VivoSeq
Other

Sprain

32

Pipeline Programs

1

Active Trials

16

Companies Involved

Sprain is a moderately active landscape with 32 programs across 16 companies. The most active players are Cerimon Pharmaceuticals, Pfizer, APR Applied Pharma Research s.a.. 16 therapies are approved with 12 more in late-stage development.

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

43/100

Completion Rate

85/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

38

clinical trials

Completed29 · 76%
Terminated4 · 11%
Unknown status3 · 8%
Withdrawn1 · 3%
Active, not recruiting1 · 3%

Trial Activity

38 trials

Topical Treatments for Ankle Sprains
Active, not recruiting··N/A·NCT06623929·100 enrolled
Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study
Completed·GSK logoGSK·Phase 3·NCT04052620·313 enrolled
Topical Ketoprofen Versus Placebo in Patients With Ankle Sprain
Completed··Phase 4·NCT02393846·100 enrolled
Approach to Ankle Sprains in the Emergency Department
Completed··Phase 4·NCT06563271·150 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)